Kuhlmann J
Clin Pharmacol Ther. 1985 Dec;38(6):667-73. doi: 10.1038/clpt.1985.243.
To determine whether verapamil, diltiazem, or nifedipine affect digitoxin kinetics, glycoside plasma concentrations and renal excretion were measured before and during steady-state dosing in 30 patients with cardiac insufficiency. The mean (+/- SD) digitoxin plasma concentration was 14.27 +/- 3.66 ng/ml before and 18.15 +/- 5.33 ng/ml during verapamil dosing in 10 patients over a period of 4 to 6 weeks. Renal digitoxin clearance was not influenced by verapamil, but total body clearance and extrarenal clearance of digitoxin were reduced by 27% and 29%, respectively. Diltiazem resulted in a 6% to 31% (mean = 21%) increase in plasma digitoxin concentrations in five of 10 patients because of reduced extrarenal clearance of digitoxin. In contrast to verapamil, the concomitant dosing of nifedipine over 4 to 6 weeks did not alter digitoxin plasma levels or daily renal excretion. Based on these observations, the risk of digitalis intoxication after combined dosing with verapamil and digitoxin is much less pronounced than that after digoxin, and thus this glycoside is a valuable alternative.
为确定维拉帕米、地尔硫䓬或硝苯地平是否影响洋地黄毒苷的药代动力学,在30例心脏功能不全患者稳态给药前及给药期间,测定了糖苷血浆浓度和肾脏排泄情况。10例患者在4至6周期间,维拉帕米给药前洋地黄毒苷血浆平均(±标准差)浓度为14.27±3.66 ng/ml,给药期间为18.15±5.33 ng/ml。维拉帕米不影响洋地黄毒苷的肾脏清除率,但洋地黄毒苷的全身清除率和肾外清除率分别降低了27%和29%。地尔硫䓬使10例患者中的5例血浆洋地黄毒苷浓度升高了6%至31%(平均为21%),原因是洋地黄毒苷的肾外清除率降低。与维拉帕米不同,硝苯地平在4至6周的联合给药期间未改变洋地黄毒苷的血浆水平或每日肾脏排泄量。基于这些观察结果,维拉帕米与洋地黄毒苷联合给药后洋地黄中毒的风险比地高辛联合给药后要小得多,因此这种糖苷是一种有价值的替代药物。